Crinetics Pharmaceuticals, Inc.
CRNXCrinetics Pharmaceuticals, Inc. (CRNX) is a biotechnology company focused on developing novel therapeutics for rare endocrine disorders and other hormonal conditions. Founded with an emphasis on hormones that regulate essential physiological processes, Crinetics designs small molecule drugs targeting specific receptor pathways to address unmet medical needs. The company's pipeline includes treatments for conditions such as acromegaly, carcinoid syndrome, and hypogonadism.
Company News
Crinetics Pharmaceuticals initiated a Phase 1/2 clinical trial for CRN09682, an investigational nonpeptide drug conjugate targeting somatostatin receptor type 2-positive neuroendocrine tumors, marking a significant milestone in developing a potentially more precise targeted therapy.
Crinetics Pharmaceuticals reported Q3 earnings with lower-than-expected revenue and increased net losses, despite receiving FDA approval for its acromegaly treatment Palsonify and securing a licensing agreement with Sanwa Kagaku Kenkyusho.
Multiple stocks saw significant gains on Friday, with Crinetics Pharmaceuticals leading the pack after FDA approval, while other companies like BlackBerry, Perpetua Resources, and Scholar Rock also experienced notable stock price increases.
Crinetics Pharmaceuticals' Chief Medical and Development Officer Dana Pizzuti sold over $645,000 worth of shares, exercising options and selling the acquired shares. The transaction was part of a pre-arranged trading plan, and Pizzuti still holds a significant stake in the company.
Crinetics Pharmaceuticals (CRNX) delivered earnings and revenue surprises of -10.71% and 21.47%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
